Safety-tolerability digest / GLP-1 receptor agonist
Semaglutide is an approved GLP-1 medicine — read here for its tolerability and safety record first.
A sober digest of what the SUSTAIN, STEP, SELECT and FLOW trials measured: the adverse-effect profile read before the headline numbers, every figure traced to the study that produced it.
The short version
Semaglutide is a prescription medicine that copies a natural gut hormone called GLP-1 (a signal your body releases after eating that tells you you are full and helps control blood sugar). It is FDA-approved to treat type 2 diabetes, to help with long-term weight management, to lower the chance of heart attack and stroke in certain people, and, since 2025, for a serious form of fatty liver disease. It is taken either as a once-a-week shot under the skin or a once-a-day pill.
This site reads the safety side first. The most common problem is an upset stomach (nausea, and sometimes vomiting, diarrhea or constipation), usually worst in the early weeks. There are a small number of more serious cautions, and a few things people report that the trials have not confirmed. What people report — including the downsides — is laid out on the effects page, and every number here is tied to a published study.
What the safety record actually shows
Read the adverse-effect profile before the headline efficacy numbers. In a pooled analysis of the weight-management trials, the gastrointestinal events that dominate semaglutide's side-effect profile — nausea, vomiting, diarrhea and constipation — were predominantly mild-to-moderate and transient, concentrated around the dose-escalation period rather than spread across treatment [8]. A dedicated safety review put nausea at roughly one in three patients and judged the overall risk/benefit profile favourable, while flagging an increased risk of gallbladder disease and pancreatic and thyroid-cancer signals for which definitive conclusions cannot yet be drawn given their low incidence [5].
The harder warnings are specific and few. GLP-1 receptor agonists (the drug class semaglutide belongs to) carry a boxed warning for thyroid C-cell tumors derived from rodent studies; a 2024 assessment found no clear human thyroid-cancer signal, but a personal or family history of medullary thyroid carcinoma is still treated as a reason not to use it [13]. In the SUSTAIN-6 cardiovascular trial, rates of diabetic-retinopathy complications were significantly higher in patients with pre-existing eye disease undergoing rapid blood-sugar correction (a hazard ratio of 1.76; 95% CI 1.11–2.78) [2]. The full account of the Semaglutide effects, with the field reports held plainly apart, is on the effects page.
Why semaglutide is studied so heavily
The reason the safety record is worth reading carefully is that the medicine works, and works at scale. In the STEP 1 trial, once-weekly subcutaneous semaglutide 2.4 mg produced a mean body-weight change of -14.9% from baseline to week 68, versus -2.4% with placebo, in adults with overweight or obesity and no diabetes [1]. In SUSTAIN-6, it reduced the composite of cardiovascular death, nonfatal heart attack or nonfatal stroke by a hazard ratio of 0.74 (95% CI 0.58–0.95) in type 2 diabetes at high cardiovascular risk [2].
The later trials extended the benefit beyond diabetes and weight. SELECT enrolled 17,604 adults with established cardiovascular disease and obesity but no diabetes and cut major adverse cardiovascular events by 20% (HR 0.80; 95% CI 0.72–0.90) [3]. FLOW, in type 2 diabetes with chronic kidney disease, reduced major kidney-disease events by 24% (HR 0.76; 95% CI 0.66–0.88) [6]. A benefit that large across so many people is exactly why the tolerability and safety questions deserve a digest of their own. The mechanism and the trial-by-trial detail sit on the Semaglutide research page.
Where semaglutide is approved
Semaglutide is not investigational and not a research chemical — it is an approved prescription medicine, and the breadth of its approvals is part of why its safety profile is unusually well characterized. It first reached FDA approval for type 2 diabetes in 2017, gained an oral once-daily formulation in 2019–2020, and added a chronic weight-management indication in 2021 [1]. On the strength of the outcome trials, a cardiovascular risk-reduction indication followed (built on SELECT) [3], a chronic-kidney-disease indication in type 2 diabetes (built on FLOW) [6], and, in 2025, an indication for a serious form of fatty liver disease (MASH).
That regulatory record matters for reading the safety evidence. Because semaglutide has been studied in tens of thousands of participants across the SUSTAIN, PIONEER and STEP programs — and then in dedicated outcome trials like SELECT (17,604 participants) [3] and FLOW (3,533 participants) [6] — its common adverse effects, its rarer signals, and its hard contraindications are documented in real human data rather than extrapolated. The compounded-product question is the exception: compounded semaglutide is not the approved manufactured product and falls outside this evidence base, a distinction this site keeps in view throughout.
How to read this site
Findings here are tiered. Established trial endpoints — the STEP weight result, the SUSTAIN-6 and SELECT cardiovascular results, the FLOW kidney result, the safety-review conclusions — are the verified spine. Cautions and honest gaps (gastrointestinal intolerance during titration, lean-mass loss, weight regain after stopping, the hair-loss signal) are flagged as cautions. Hard contraindications (the boxed thyroid warning, pregnancy, the pancreatitis class warning) are flagged as such. And anything people report in patient communities that controlled trials have not confirmed is held in a clearly separated field-reports block, never mixed in with a trial endpoint.
The dose figures throughout are reported exactly as they appear in the cited trials and labeling — third person, as documented, never as advice for any individual. Two dedicated pages dig into the questions readers ask most about tolerability: semaglutide hair loss and semaglutide muscle loss. The full citation list is on the Semaglutide references page.